Subscribe To
ALDX / Why Are Stocks Up Today?
ALDX News
By PennyStocks
November 1, 2023
5 Most Active Penny Stocks Today & Why They're Moving Now
Penny stocks are the wild west of the stock market. Fast-paced, unpredictable, and laden with potential treasures. more_horizontal
By InvestorPlace
November 1, 2023
Why Are Stocks Up Today?
Stocks are up today as investors prepare for the latest information from the Federal Reserve concerning interest rates. The Federal Open Market Commit more_horizontal
By InvestorPlace
November 1, 2023
Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today?
Aldeyra Therapeutics (NASDAQ: ALDX ) stock is on the rise Wednesday after entering into an exclusive option agreement with AbbVie (NYSE: ABBV ). This more_horizontal
By Market Watch
October 16, 2023
Aldeyra Therapeutics stock plunges on heavy volume after FDA finds ‘substantive' issues with NDA for dry-eye disease treatment
Shares of Aldeyra Therapeutics Inc. ALDX, -66.43% plummeted 61.9% toward a 3 1/2-year low in very active morning trading Monday, enough to pace the Na more_horizontal
By Proactive Investors
October 16, 2023
Aldeyra Therapeutics stock tanks on warning that FDA will reject new drug application
Shares of Aldeyra Therapeutics (NASDAQ:ALDX) have lost two-thirds of their value Monday after the company warned the US Food and Drug Administration m more_horizontal
By Seeking Alpha
September 22, 2023
Aldeyra:Upcoming PDUFA, Strong NDA, Long Pipeline, Decent Cash
Aldeyra is a late-stage company developing therapies for immune-mediated diseases, with a focus on dry eye disease and allergic conjunctivitis. Their more_horizontal
By Seeking Alpha
July 10, 2023
Aldeyra Therapeutics: Navigating The Future Of Eye Disease Treatment With Reproxalap
Aldeyra Therapeutics reported $165 million in cash and cash equivalents as of March 31, 2023, with a net loss of $15.6 million for Q1 2023. The compan more_horizontal
By Zacks Investment Research
June 16, 2023
Aldeyra (ALDX) Up On Positive Data From Conjunctivitis Study
Aldeyra (ALDX) soars on meeting primary and secondary endpoints in the late-stage study of reproxalap for patients with allergic conjunctivitis. more_horizontal